Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

UBLITUXIMAB vs UBROGEPANT: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

UBLITUXIMAB vs UBROGEPANT: Safety Overview

Metric UBLITUXIMAB UBROGEPANT
Total FAERS Reports 1,582 2,531
Deaths Reported 27 49
Death Rate 1.7% 1.9%
Hospitalizations 213 145
Average Patient Age 49.7 yrs 49.2 yrs
% Female Patients 73.4% 83.6%
FDA Approval Date N/A Dec 23, 2019
Manufacturer TG Therapeutics, Inc. Allergan, Inc.
Route INTRAVENOUS ORAL
Marketing Status N/A Prescription